ReNerve

ReNerve EBITDA per Share

The EBITDA per Share of ReNerve (RNV.AX) as of Oct 25, 2026 is -0.04 AUD. In the previous year, EBITDA per Share was -0.03 AUD — a change of 22.27% (lower).

EBITDA per Share

-0.04AUD

YoY

22.27%

Last updated:

EBITDA per Share of ReNerve is 2026 -0.04 AUD. EBITDA per Share of ReNerve was 2025 -0.03 AUD. It decreases by 22.27% lower compared to the previous year.

The ReNerve EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2022
-0.01 AUD
Jan 1, 2023
-0.01 AUD
Jan 1, 2024
-0.02 AUD
Jan 1, 2025
-0.03 AUD
Jan 1, 2026
-0.04 AUD
The ReNerve EBITDA per Share history
YEAREBITDA per ShareYoY
-0.04AUD+22.27%
-0.03AUD+79.68%
-0.02AUD+44.69%
-0.01AUD+18.09%
-0.01AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReNerve Stock analysis

What does ReNerve do? ReNerve Ltd develops medical devices for nerve repair and soft tissue surgery, focusing on products that accelerate regeneration and prevent scarring. The company offers NervAlign Nerve Cuff, a protective wrap for repaired nerves, and NervAlign Nerve Graft, which allows surgeons to repair damaged nerves without harvesting the sural nerve. NervAlign Bionic Nerve combines polymer technology with nerve grafts to create a replacement nerve using shaped ionic polymers for distal nerve stimulation. These products target surgical procedures requiring nerve repair, with hospitals and surgical centers as primary buyers. The company's revenue comes from selling NervAlign products directly to healthcare providers involved in nerve repair surgeries. NervAlign Nerve Cuff is designed for protecting repaired nerves during surgery, while NervAlign Nerve Graft eliminates the need for patient nerve harvesting. NervAlign Bionic Nerve represents a future product line aiming to provide advanced nerve replacement solutions. The target market includes surgical teams specializing in peripheral nerve procedures and medical facilities equipped for complex soft tissue surgeries. ReNerve Ltd's products are positioned for use in peripheral nerve repair and related soft tissue surgical procedures. The NervAlign Nerve Cuff protects injured nerves during surgical repair, the NervAlign Nerve Graft enables nerve repair without patient nerve harvesting, and NervAlign Bionic Nerve aims to stimulate distal nerve ends using ionic polymers. These products are sold to hospitals and surgical centers that perform nerve repair surgeries, with the company focusing on accelerating tissue regeneration and reducing complications. ReNerve is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReNerve stock

EBITDA per Share of ReNerve is -0.04 AUD in 2026.

EBITDA per Share of ReNerve changed from -0.03 AUD to -0.04 AUD, representing a 22.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share ReNerve since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ReNerve

All Key Metrics — ReNerve